Provide advanced sequencing and array-based solutions for genetic and genomic analysis. Develop instruments and consumables essential for genetic analysis. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
The market pays 36.7× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 44% of them.
Analysts' average target sits 2% above today's price.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly below the class average.
This grade is a blend: the profit side is strong, the sales tempo slow.
The stock has been running stronger than the market lately.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 20% — still a thick cushion, though costs have been eating into it lately.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 3 years, sales fell about 1% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 37 times its annual profit. Even a small disappointment could hit the price hard.
Over the last 12 months, executives reported 150 sells against just 48 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, ILMN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ILMN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.